BridgeBio Oncology Therapeutics (BBOT) EBIT (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted EBIT of -$46.2 million for Q1 2026, down 6.38% sequentially from -$43.4 million in Q4 2025, and down 99.59% YoY from -$11.2 billion in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) EBIT (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported EBIT for 3 years, with the latest figure at -$46.2 million in Q1 2026.
- Quarterly EBIT fell 99.59% year-over-year to -$46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$139.9 million (down 115.77% YoY) and the FY2025 annual result came in at -$145.8 million, down 80.33% from the prior year.
- EBIT slipped to -$46.2 million in Q1 2026 per BBOT's latest filing, from -$43.4 million in the prior quarter.
- Over five years, EBIT peaked at -$66701.0 in Q1 2024 and troughed at -$49.2 million in Q3 2025.
- A 3-year average of -$22.8 million and a median of -$21.9 million in 2024 frame the typical range for EBIT.
- The widest YoY moves for EBIT: up 98.4% in 2025, down 34587.64% in 2025.
- Over 3 years, EBIT stood at -$21.9 million in 2024, then plunged by 98.4% to -$43.4 million in 2025, then dropped by 6.38% to -$46.2 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$46.2 million, -$43.4 million, and -$49.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | -60.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.19 Mn |
| Mar 31, 2026 | -46.18 Mn |
| Dec 31, 2025 | -43.41 Mn |
| Sep 30, 2025 | -49.18 Mn |
| Jun 30, 2025 | -1.12 Mn |
| Mar 31, 2025 | -23.14 Mn |
| Dec 31, 2024 | -21.88 Mn |
| Sep 30, 2024 | -19.66 Mn |
| Jun 30, 2024 | -152,343.00 |
| Mar 31, 2024 | -66,701.00 |